ANNUAL REPORT HOME
ABOUT GENZYME
SITEMAP
LEGAL DISCLAIMER
2006 Annual Report
TABLE OF CONTENTS
Financial Highlights
Letter to Shareholders
Our Passion
Our Presence
Our Portfolio
Our Engine is Innovation
Renal Disease
Genetic Diseases
Orthopaedics/Biosurgical Specialties
Oncology/Endocrinology
Transplant/Immune Diseases
Genetics/Diagnostics
Our Pipeline
Our Commitment
Our Social Responsibility
Our Employees
2006 Annual Report Sitemap
Financial Highlights
Summary of Operations
Financial Position
Letter to Shareholders
Continued Investment
Rapid Myozyme Launch
Optimizing Existing Products
High-Impact Late-Stage Programs
Commitment to Innovation
A Clear Sense of Purpose
Our Passion
Our Presence
Global Network
Manufacturing and Distribution
Clinical and Regulatory Affairs
Our Portfolio
Genetics/Diagnostics
Genetic Diseases
Renal Disease
Orthopaedics/Biosurgical Specialties
Oncology/Endocrinology
Transplant/Immune Diseases
Our Engine is Innovation
Tolevamer
Mozobil
Alemtuzumab
Renal Disease
Rapid Growth for Renagel Around The World
Next-Generation Progress
Chronic Kidney Disease
Genetic Diseases
Myozyme Launched Worldwide
Cerezyme: Available Around The World
Fabrazyme: Driven by New Data
Continued Progress and Investment
Orthopaedics/Biosurgical Specialties
Continuing Leadership with Synvisc
Innovation And Investment
Sepra Products Developments
Oncology/Endocrinology
Campath: Nearing First-Line Status
Expanding Clolar to Adults
Thyroid Cancer/Endocrinology
Transplant/Immune Diseases
Thymoglobulin: Growing, Global
Mozobil for Bone Marrow Transplantation
Genetics/Diagnostics
Genzyme's Leadership
Reproductive and Oncology Testing
Diagnostic Products
Our Pipeline
Genetics/Diagnostics Pipeline
Product Development Pipeline
Our Commitment
Our Social Responsibility
Access to Information and Therapy
Supporting Global Health and Local Communities
Our Employees
Individual Leadership
Recognized for Excellence